Skip to content

Study · Animal study (in vivo) · rat (sprague-dawley) · 2021

8 results

Effect of kisspeptin-54 on ovarian levels of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in an experimental model of ovarian hyperstimulation syndrome (OHSS).

Birinci H, Vatansever HS, Yüncü M

Reproduction, fertility, and development1 Nov 2021Cited by 2 (Europe PMC)

PMID34610858 (opens in a new tab)DOI10.1071/rd21140 (opens in a new tab)PepBankPUB-34610858
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In OHSS model rats, kisspeptin‑54 treatment reduced the fallopian tube dilatation seen in the OHSS group.

    In plain wordsIn rats with ovarian hyperstimulation, kisspeptin‑54 reduced the widening of the fallopian tubes.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseFallopian tube dilatation
    Study

    rat (Sprague-Dawley)n: not reported in source

    Ovarian hyperstimulation syndrome (OHSS) rat model
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was observed that there was dilatation in fallopian tubes and an abnormal increase in ovarian weight and volume in the OHSS group, and these morphologies decreased with kisspeptin-54 treatment.
    1 context sentence
    Summary · context
    For this purpose, immature female Sprague-Dawley rats (25days old, 30-40g) were randomly divided into five groups (control, sham, OHSS model, short-term kisspeptin-54 administered OHSS model and long-term kisspeptin-54 administered OHSS model).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In OHSS model rats, kisspeptin‑54 treatment reduced the abnormal increase in ovarian weight.

    In plain wordsIn rats with ovarian hyperstimulation, kisspeptin‑54 reduced the abnormal gain in ovary weight.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseOvarian weight
    Study

    rat (Sprague-Dawley)n: not reported in source

    Ovarian hyperstimulation syndrome (OHSS) rat model
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was observed that there was dilatation in fallopian tubes and an abnormal increase in ovarian weight and volume in the OHSS group, and these morphologies decreased with kisspeptin-54 treatment.
    1 context sentence
    Summary · context
    For this purpose, immature female Sprague-Dawley rats (25days old, 30-40g) were randomly divided into five groups (control, sham, OHSS model, short-term kisspeptin-54 administered OHSS model and long-term kisspeptin-54 administered OHSS model).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In OHSS model rats, kisspeptin‑54 treatment reduced the abnormal increase in ovarian volume.

    In plain wordsIn rats with ovarian hyperstimulation, kisspeptin‑54 reduced the abnormal gain in ovary size.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseOvarian volume
    Study

    rat (Sprague-Dawley)n: not reported in source

    Ovarian hyperstimulation syndrome (OHSS) rat model
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was observed that there was dilatation in fallopian tubes and an abnormal increase in ovarian weight and volume in the OHSS group, and these morphologies decreased with kisspeptin-54 treatment.
    1 context sentence
    Summary · context
    For this purpose, immature female Sprague-Dawley rats (25days old, 30-40g) were randomly divided into five groups (control, sham, OHSS model, short-term kisspeptin-54 administered OHSS model and long-term kisspeptin-54 administered OHSS model).
  4. 04AnimalAnimal study (in vivo)Mechanism

    In OHSS model rats, kisspeptin‑54 reduced VEGF at the mRNA and protein level.

    In plain wordsIn rats with ovarian hyperstimulation, kisspeptin‑54 lowered VEGF, a blood vessel growth factor, in the ovaries.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseOvarian VEGF mRNA and protein
    Study

    rat (Sprague-Dawley)n: not reported in source

    Ovarian hyperstimulation syndrome (OHSS) rat model
    Outcome group
    Inflammation markers · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After the administration of kisspeptin-54 in the OHSS group, VEGF, PKA and PKC levels reduced and PEDF levels increased in both mRNA and protein levels.
    1 context sentence
    Summary · context
    For this purpose, immature female Sprague-Dawley rats (25days old, 30-40g) were randomly divided into five groups (control, sham, OHSS model, short-term kisspeptin-54 administered OHSS model and long-term kisspeptin-54 administered OHSS model).
  5. 05AnimalAnimal study (in vivo)Mechanism

    In OHSS model rats, kisspeptin‑54 reduced PKA at the mRNA and protein level.

    In plain wordsIn rats with ovarian hyperstimulation, kisspeptin‑54 lowered the signalling enzyme PKA in the ovaries.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseOvarian PKA mRNA and protein
    Study

    rat (Sprague-Dawley)n: not reported in source

    Ovarian hyperstimulation syndrome (OHSS) rat model
    Outcome group
    Receptor activity and mechanism · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After the administration of kisspeptin-54 in the OHSS group, VEGF, PKA and PKC levels reduced and PEDF levels increased in both mRNA and protein levels.
    1 context sentence
    Summary · context
    For this purpose, immature female Sprague-Dawley rats (25days old, 30-40g) were randomly divided into five groups (control, sham, OHSS model, short-term kisspeptin-54 administered OHSS model and long-term kisspeptin-54 administered OHSS model).
  6. 06AnimalAnimal study (in vivo)Mechanism

    In OHSS model rats, kisspeptin‑54 reduced PKC at the mRNA and protein level.

    In plain wordsIn rats with ovarian hyperstimulation, kisspeptin‑54 lowered the signalling enzyme PKC in the ovaries.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseOvarian PKC mRNA and protein
    Study

    rat (Sprague-Dawley)n: not reported in source

    Ovarian hyperstimulation syndrome (OHSS) rat model
    Outcome group
    Receptor activity and mechanism · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After the administration of kisspeptin-54 in the OHSS group, VEGF, PKA and PKC levels reduced and PEDF levels increased in both mRNA and protein levels.
    1 context sentence
    Summary · context
    For this purpose, immature female Sprague-Dawley rats (25days old, 30-40g) were randomly divided into five groups (control, sham, OHSS model, short-term kisspeptin-54 administered OHSS model and long-term kisspeptin-54 administered OHSS model).
  7. 07AnimalAnimal study (in vivo)Mechanism

    In OHSS model rats, kisspeptin‑54 increased PEDF at the mRNA and protein level.

    In plain wordsIn rats with ovarian hyperstimulation, kisspeptin‑54 raised PEDF, a factor that counters blood vessel growth, in the ovaries.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseOvarian PEDF mRNA and protein
    Study

    rat (Sprague-Dawley)n: not reported in source

    Ovarian hyperstimulation syndrome (OHSS) rat model
    Outcome group
    Inflammation markers · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After the administration of kisspeptin-54 in the OHSS group, VEGF, PKA and PKC levels reduced and PEDF levels increased in both mRNA and protein levels.
    1 context sentence
    Summary · context
    For this purpose, immature female Sprague-Dawley rats (25days old, 30-40g) were randomly divided into five groups (control, sham, OHSS model, short-term kisspeptin-54 administered OHSS model and long-term kisspeptin-54 administered OHSS model).
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In OHSS model rats, long-term kisspeptin‑54 treatment was more effective than short-term administration.

    In plain wordsIn rats with ovarian hyperstimulation, long-term kisspeptin‑54 treatment worked better than short-term treatment.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    Not applicableLong-term versus short-term kisspeptin-54 treatment
    Study

    rat (Sprague-Dawley)n: not reported in source

    Ovarian hyperstimulation syndrome (OHSS) rat model
    Comparator
    Short-term kisspeptin-54 administration
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was determined that long-term kisspeptin-54 treatment was more effective than short-term administration.
    1 context sentence
    Summary · context
    For this purpose, immature female Sprague-Dawley rats (25days old, 30-40g) were randomly divided into five groups (control, sham, OHSS model, short-term kisspeptin-54 administered OHSS model and long-term kisspeptin-54 administered OHSS model).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.